Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 5/20 | 1.00 |
| ▸ | AXL | P30530 | 2/20 | 0.59 |
| ▸ | IDO1 | P14902 | 3/20 | 0.55 |
| ▸ | METAP2 | P50579 | 2/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | RARG | P13631 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4314318 | 1.00 | NOS1 (1.00) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL30234107 | 1.00 | NOS1 (1.00) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL18669085 | 0.76 | NOS1 (0.60) | NOS1AXLIDO1JAK2JAK1 | |
| SCHEMBL12601112 | 0.76 | NOS1 (0.61) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL10594553 | 0.75 | NOS1 (0.59) | NOS1AXLIDO1METAP2TRPA1 | |
| SCHEMBL277054 | 0.74 | NOS1 (0.59) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL18193497 | 0.74 | NOS1 (0.59) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL277055 | 0.74 | NOS1 (0.59) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL155255 | 0.74 | NOS1 (1.00) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL5951586 | 0.74 | AXL (0.63) | NOS1AXLIDO1METAP2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 350 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111995577-A | Synthetic method of 4-fluoro indazole 3-carbonitrile or derivatives thereof | 上海代为化学科技有限公司 | 2020-11-27 | — | — | CN | claimed |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250353829-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYSOWAY THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119569700-A | 6-Nitrogen-containing cyclopicolinic acid and partial formate compound thereof, and preparation method and application thereof | 中国农业大学 | 2025-03-07 | — | — | CN | disclosed |
| CN-119562945-A | IKK inhibitors | 癌症研究技术有限公司 | 2025-03-04 | — | — | CN | disclosed |
| US-12215093-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| WO-2024220747-A2 | FLUORINATED CYCLIC DERIVATIVES OF SULFONAMIDES AND SULFONES, AND COMPOSITIONS AND METHODS THEREOF | Lysoway Therapeutics, Inc. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2000064889-A1 | HERBICIDAL 3-(HETEROCYCL-1-YL)-URACILS | AMERICAN CYANAMID COMPANY (US) | 2000-11-02 | — | — | WO | disclosed |
| WO-2000064890-A1 | HERBICIDAL 3-(HETEROCYCL-1-YL)-URACILS | AMERICAN CYANAMID COMPANY (US) | 2000-11-02 | — | — | WO | disclosed |
| US-6046136-A | FOR CONTROLLING WEEDS | ZENECA LIMITED (GB) | 2000-04-04 | — | — | US | disclosed |
| US-5911899-A | Corrosion-proof transparent heater panels and preparation process thereof | MITSUI CHEMICALS, INC. (JP) | 1999-06-15 | — | — | US | disclosed |
| EP-0657450-B1 | INDAZOLESULFONYLUREA DERIVATIVE, USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | KUMIAI CHEMICAL INDUSTRY CO (JP) | 1998-09-09 | — | — | EP | disclosed |
| US-5763616-A | HERBICIDES | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1998-06-09 | — | — | US | disclosed |
| US-5670452-A | PREEMERGENCE HERBICIDES | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1997-09-23 | — | — | US | disclosed |
| EP-0749266-A2 | Transparent heater panels and method of making them | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1996-12-18 | — | — | EP | disclosed |
| US-5534481-A | Indazolesulfonylurea derivative, its use and intermediate for its production | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1996-07-09 | — | — | US | disclosed |
| EP-0657450-A1 | INDAZOLESULFONYLUREA DERIVATIVE, USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | KumaiI Chemical Industry Co., Ltd. (JP) | 1995-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | NOS1 1221/4885AXL 1479/4885IDO1 1065/4885 |
| US-20250353829-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | NOS1 3363/4885AXL 2869/4885IDO1 1260/4885 |
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | STOML2, ATP2A3, ATP2A1 | NOS1 4223/4885AXL 2312/4885IDO1 4856/4885 |
| US-12215093-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | NOS1 3363/4885AXL 2869/4885IDO1 1260/4885 |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3C2B, PIK3C2A, PIK3R1 | NOS1 1992/4885AXL 613/4885IDO1 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.